Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics

被引：114

作者：

Linehan, W. Marston

Pinto, Peter A.

Srinivasan, Ramaprasad

Merino, Maria

Choyke, Peter

Choyke, Lynda

Coleman, Jonathan

Toro, Jorge

Glenn, Gladys

Vocke, Cathy

Zbar, Bert

Schmidt, Laura S.

Bottaro, Donald

Neckers, Len

机构：

[1] NCI, Urol Oncol Branch, Bethesda, MD 20892 USA

[2] NCI, Pathol Lab, Bethesda, MD 20892 USA

[3] NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD 20892 USA

[4] NCI, Genet Epidemiol Branch, Bethesda, MD 20892 USA

[5] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA

[6] NCI, Basic Res Program, Sci Applicat Int Corp, Frederick Inc, Frederick, MD 21701 USA

来源：

CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 02期

关键词：

D O I：

10.1158/1078-0432.CCR-06-1870

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent advances in understanding the kidney cancer gene pathways has provided the foundation for the development of targeted therapeutic approaches for patients with this disease. Kidney cancer is not a single disease; it includes a number of different types of renal cancers, each with different histologic features, a different clinical course, a different response to therapy, and different genes causing the defects. Most of what is known about the genetic basis of kidney cancer has been learned from study of the inherited forms of kidney cancer: von Hippel Lindau (VHL gene), hereditary papillary renal carcinoma (c-Met gene), Birt Hogg Dube (BHD gene), and hereditary leiomyomatosis renal cell cancer (fumarate hydratase gene). These Mendelian single-gene syndromes provide a unique opportunity to evaluate the effectiveness of agents that target the VHL, c-Met, BHD, and fumarate hydratase pathways.

引用

收藏

页码：671S / 679S

页数：9

相关论文

共 100 条

[1] Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx [J].

Aebersold, DM ;

Landt, O ;

Berthou, S ;

Gruber, G ;

Beer, KT ;

Greiner, RH ;

Zimmer, Y .

ONCOGENE, 2003, 22 (52) :8519-8523

[2] Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth [J].

Bardelli, A ;

Longati, P ;

Gramaglia, D ;

Basilico, C ;

Tamagnone, L ;

Giordano, S ;

Ballinari, D ;

Michieli, P ;

Comoglio, PM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14379-14383

[3] The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants [J].

Berthou, S ;

Aebersold, DM ;

Schmidt, LS ;

Stroka, D ;

Heigl, C ;

Streit, B ;

Stalder, D ;

Gruber, G ;

Liang, CX ;

Howlett, AR ;

Candinas, D ;

Greiner, RH ;

Lipson, KE ;

Zimmer, Y .

ONCOGENE, 2004, 23 (31) :5387-5393

[4] Met, metastasis, motility and more [J].

Birchmeier, C ;

Birchmeier, W ;

Gherardi, E ;

Vande Woude, GF .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925

[5] HEREDITARY MULTIPLE FIBROFOLLICULOMAS WITH TRICHODISCOMAS AND ACROCHORDONS [J].

BIRT, AR ;

HOGG, GR ;

DUBE, WJ .

ARCHIVES OF DERMATOLOGY, 1977, 113 (12) :1674-1677

[6] Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors [J].

Burgess, T ;

Coxon, A ;

Meyer, S ;

Sun, J ;

Rex, K ;

Tsuruda, T ;

Chen, Q ;

Ho, SY ;

Li, L ;

Kaufman, S ;

McDorman, K ;

Cattley, RC ;

Sun, JL ;

Elliott, G ;

Zhang, K ;

Feng, X ;

Jia, XC ;

Green, L ;

Radinsky, R ;

Kendall, R .

CANCER RESEARCH, 2006, 66 (03) :1721-1729

[7] Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models [J].

Cao, B ;

Su, YL ;

Oskarsson, M ;

Zhao, P ;

Kort, EJ ;

Fisher, RJ ;

Wang, LM ;

Vande Woude, GF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (13) :7443-7448

[8] Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity [J].

Chiara, F ;

Michieli, P ;

Pugliese, L ;

Comoglio, PM .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (31) :29352-29358

[9] Endolymphatic sac tumors in von Hippel-Lindau disease [J].

Choo, D ;

Shotland, L ;

Mastroianni, M ;

Glenn, G ;

Van Waes, C ;

Linehan, WM ;

Oldfield, EH .

JOURNAL OF NEUROSURGERY, 2004, 100 (03) :480-487

[10] c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention [J].

Christensen, JG ;

Burrows, J ;

Salgia, R .

CANCER LETTERS, 2005, 225 (01) :1-26

← 1 2 3 4 5 6 7 8 9 10 →